摘要
目的 回顾性研究维奈克拉联合阿扎胞苷方案治疗高危骨髓增生异常综合征(MDS)的有效性及安全性。方法 选取平顶山市第二人民医院2021年2月至2023年9月收治的高危MDS患者临床资料,根据1∶1配对原则将60例分为两组,给予阿扎胞苷治疗的30例为对照组,给予维奈克拉联合阿扎胞苷治疗的30例为研究组。对比两组疗效、不良反应、血小板(PLT)恢复时间、PLT悬液输注量、疲劳状态评分及免疫调控因子[β2微球蛋白(β2-MG)、白细胞介素-10(IL-10)、T细胞免疫球蛋白3(TIM-3)]水平。结果 研究组总有效率高于对照组(P<0.05);两组PLT恢复时间、PLT悬液输注量及不良反应发生率相比,差异无统计学意义(P>0.05);治疗1、3个疗程后研究组疲劳状态评分低于对照组(P<0.05);治疗1、3疗程后研究组TIM-3、IL-10、β2-MG水平低于对照组(P<0.05)。结论 维奈克拉联合阿扎胞苷治疗高危MDS的效果较好,可控制病情发展,缓解疲劳状态,耐受性好。
Objective To review the efficacy and safety of vinecra combined with azacytidine in the treatment of high-risk myelodysplastic syndrome(MDS).Methods Clinical data of high-risk MDS patients admitted to Pingdingshan Second People’s Hospital from February 2021 to September 2023 were selected,and 60 cases were divided into two groups according to 1∶1 pairing principle.Thirty cases treated with azacitidine were seted as control group,and 30 cases treated with vinecra and azacitidine were seted as study group.The efficacy,adverse reactions,platelet(PLT)recovery time,PLT suspension infusion volume,fatigue state score and immune regulatory factors[β2 microglobulin(β2-MG),interleukin-10(IL-10),T cell immunoglobulin 3(TIM-3)]levels were compared between the two groups.Results The total effective rate of the study group was higher than that of the control group(P<0.05).There was no statistical difference in PLT recovery time,PLT suspension infusion volume and incidence of adverse reactions between the two groups(P>0.05).After 1 and 3 courses of treatment,the fatigue score of the study group was lower than that of the control group(P<0.05).The levels of TIM-3,LI-10 andβ2-MG in the study group were lower than those in the control group after 1 and 3 courses of treatment(P<0.05).Conclusion Veneckla combined with azacitidine is effective in the treatment of high-risk MDS,which can control the progression of the disease,relieve fatigue and be well tolerated.
作者
陈建玲
杨洋
胡宝花
CHEN Jianling;YANG Yang;HU Baohua(Department of Hematology,Pingdingshan Second People’s Hospital,Pingdingshan 467000,China)
出处
《河南医学研究》
CAS
2024年第20期3769-3773,共5页
Henan Medical Research
